Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 648

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 3
Chunk 648
---
Sean MacDonald

			35,000

			39,738

			74,738

			Patrick Marshall

			48,536

			21,855

			70,391

			Charles Olson, DSc

			44,000

			21,855

			65,855

			Carlo Sistilli, CPA, CMA

			65,000

			39,738

			104,738

			Frank R. Oakes (5)

			31,942

			34,372

			66,314

			(1)

			The compensation paid to each of Ms. Chypyha, Mr. MacDonald, Mr. Marshall and Mr. Sistilli was paid in Canadian dollars and was converted from US dollars using the average foreign exchange rate for each month of the year from oanda.com.

			(2) 
			
			The amounts shown in this column represent the aggregate grant date fair value of the restricted share units computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 718, not the actual amounts paid to or realized by the directors during the covered fiscal year. The assumptions used in determining grant date fair value of these awards are set forth in Note 7 to our audited consolidated financial statements for the year ended September 30, 2025 included in this Annual Report.

			(3) 

			As of September 30, 2025, (i) Ms. Chypyha and Mr. Marshall each held 11,000 RSUs, (ii) Mr. Liu held 3,669 RSUs, (iii) Mr. MacDonald and Mr. Sistilli each held 20,001 RSUs, (iv) Mr. Olson held 7,332 RSUs and Mr. Oakes held 11,532 RSUs.

			(4) 

			There were no share options grants in the year ended September 30, 2025. As of September 30, 2025, (i) Ms. Chypyha, Mr. Marshall and Dr. Olson each held 2,858 share options, (ii) Mr. MacDonald and Mr. Sistilli each held 11,773 share options, (iii) Mr. Oakes held 11,773 share options and (iv) Dr. Liu held no share options.

			(5)